Table 4.
Donor
|
Recipient
|
Percent of transductants with donor phenotype* DnaC+ Hsd− | ||
---|---|---|---|---|
Strain | Phenotype | Strain | Phenotype | |
NM840 | rK−mK− | NM827 | rK+mK+ | 23 (14/61) |
NM865 | rK+mK+ | 50 (15/30) | ||
NM840 | rK−mK− | NM822 | rK−mK+, HsdC− | 36 (20/55) |
NM866 | rK−mK+, HsdC− | 50 (12/24) | ||
NM840 | rK−mK− | NM846 | rK+mK+, HsdC− | 25 (21/80) |
NM840 | rK−mK− | NM839 | rK+mK+, HsdC− | 50 (27/54) |
NM515 | rD+mD+ | NM846 | rK+mK+, HsdC− | — (0/85)† |
NM515 | rD+mD+ | NM839 | rK+mK+, HsdC− | — (0/26)† |
Percent with DnaC+ TetS phenotype varied from 66% to 84%.
Absence of rD+mD+ transductants confirms HsdC− phenotype of recipient.